Prof Sanyal describes the histological spectrum from NAFL to NASH and explains the regulatory pathway for the approval for therapies in the field of NASH. It includes selecting the right target, the right population, the right safety and the right efficacy.

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In

5 − four =